Earli locates cancer early, when it is much more curable. Rather than rely on biomarkers that cancer may – or often may not – naturally provide, Earli's technology “forces” cancer cells to make a precise synthetic, non-human biomarker to localize the cancer. This new approach is called synthetic biopsy. In the future, the same platform might also be usable to trigger localized therapeutic responses inside the cancer.

Visite el sitio web de Earli

Suscribirse a las actualizaciones

Una actualización semanal de lo que hay en la Agenda Global

© 2021 World Economic Forum

Política de privacidad y normas de uso